The global LVAD market to grow at a CAGR of 13.19% during the period 2016-2020.
Global Left Ventricular Assist Device (LVAD) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
A trend that is sure to boost market growth is the increase in M&A. Vendors undergo M&A to extend their product offerings, increase their market share, and expand their operations. They acquire other companies to enhance their R&D capabilities for manufacturing innovative devices that can meet consumer needs. Acquisition of other companies allows vendors access to the product portfolio of the acquired company.
M&A also helps new players enter the market. In 2013, Thoratec acquired the rights to Terumo Heart's DuraHeart II ventricular assist system. In 2014, Thoratec acquired Apica Cardiovascular to expand its LVAD product portfolio. In October 2015, St. Jude Medical acquired Thoratec for about $3.3 billion. In September 2015, HeartWare International entered into a definitive agreement to acquire Valtech Cardio.
According to the report, a key growth driver is the shortage of heart donors. CVDs can sometimes lead to severe heart failure. In such cases, it becomes mandatory for people to undergo heart transplantation. However, it is difficult to obtain heart transplants due to the shortage of heart donors.
The number of people worldwide that require heart transplantations is rising with each passing year, but there has not been a corresponding rise in heart donors, which is leading to an increase in the average waiting time for heart transplantation. The average waiting time for heart transplantation in the US is 9-11 months. However, in most cases, it goes up to two years. In 2013, the Health Resources and Services Administration estimated that about 18 people die every day in the US due to a shortage of donor hearts.
Further, the report states that one challenge that could impact market growth is the availability of alternative treatments. The presence of alternative treatment options, such as heart transplantation, drug therapy, and TAHs to address acute heart failure and improve cardiac output, hinder the sales of LVADs.
- Abiomed - Berlin Heart - HeartWare International - Jarvik Heart - St. Jude Medical
Other prominent vendors
- Cardiac Assist - Evaheart - ReliantHeart - Sun Medical Technology Research - Sunshine Heart